Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment

Clinical Pharmacokinetics

Volumn 45, Issue 11, 2006, Pages 1115-1124

  Kearney, Brian P ^a   Yale, Kitty ^a   Shah, Jaymin ^a   Zhong, Lijie ^a   Flaherty, John F ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR DISOPROXIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM;

ADENINE; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; LIVER DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHOSPHONIC ACIDS; RENAL DIALYSIS; RENAL INSUFFICIENCY; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 33750335645     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645110-00005     Document Type: Article

References (16)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13): 853-60
2. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL: http://AIDSinfo.nih.gov [Accessed 2005 Oct 6]
3. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004 Mar 1; 189 (5): 837-46
4. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004 Jul 14; 292 (2): 191-201
5. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354 (3): 251-60
6. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother 2001; 45 (10): 2733-9
7. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43 (9): 595-612
8. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy [letter]. AIDS 1998 Jul 9; 12 (10): 1256
9. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000 Jan 5; 283 (1): 74-80
10. D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998 Jul; 18 (4): 406-21
11. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001 Jun 28; 344 (26): 1979-84
12. Kearney BP, Liaw S, Yale K, et al. Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment [poster]. Sixth International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow
13. Kearney BP, Benhamou Y, Flaherty J, et al. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis [poster no. 600]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
15. Kearney BP, Ramanathan S, Cheng AK, et al. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration. J Clin Pharmacol 2005 Aug; 45 (8): 935-40
16. Viread. VIREAD® (US Prescribing Information). Foster City (CA): Gilead Sciences Inc, 2005